| Literature DB >> 31845898 |
Gabriele Giannola1, Riccardo Torcivia1, Riccardo Airò Farulla1, Tommaso Cipolla1.
Abstract
BACKGROUND: Remote management is partially replacing routine follow-up in patients implanted with cardiac implantable electronic devices (CIEDs). Although it reduces clinical staff time compared with standard in-office follow-up, a new definition of roles and responsibilities may be needed to review remote transmissions in an effective, efficient, and timely manner. Whether remote triage may be outsourced to an external remote monitoring center (ERMC) is still unclear.Entities:
Keywords: cardiac implantable electronic devices; follow-up; implantable cardioverter defibrillator; implantable defibrillators; pacemaker; remote monitoring; telemonitoring; triage outsourcing
Year: 2019 PMID: 31845898 PMCID: PMC6938593 DOI: 10.2196/cardio.9815
Source DB: PubMed Journal: JMIR Cardio ISSN: 2561-1011
Figure 1Remote management flowchart. Green events are all transmissions not reporting device detections listed as low or high priority. In case of missed scheduled transmissions or disconnected monitors, the external remote monitoring center (ERMC) inform the technical team responsible for contacting the patient. RRT: recommended replacement time; TAO: oral anticoagulation therapy; AT/AF: atrial tachyarrhythmia/atrial fibrillation; CRT: cardiac resynchronization therapy; SVC: superior vena cava. DOO, VOO, and AOO are programming modes.
Demographics and baseline patient characteristics.
| Patient characteristics | Total (N=153) | CRT-Da (N=76) | ICDb (N=15) | IPG+CRT-Pc (N=62) | |
|
| |||||
|
| Age at first implant (years), mean (SD) | 68 (11) | 69 (9) | 64 (13) | 68 (13) |
|
| Male, n (%) | 112 (73.2) | 55 (72) | 15 (100) | 42 (68) |
|
| |||||
|
| Ischemic cardiopathy | 56 (37) | 31 (41) | 11 (73) | 14 (23) |
|
| Acute myocardial infarction | 35 (23) | 28 (37) | 7 (47) | 0 (0 ) |
|
| History of heart failure | 107 (70.0) | 67 (88) | 5 (27) | 35 (56) |
|
| New York Heart Association III-IV | 54 (35) | 56 (74) | 2 (13) | 0 (0) |
|
| History of ventricular tachycardia/ventricular fibrillation | 36 (24) | 27 (36) | 5 (33) | 4 (7) |
|
| Ventricular fibrillation/flutter | 2 (1) | 2 (3) | 0 (0) | 0 (0) |
|
| History of atrial tachycardia/atrial fibrillation | 72 (47) | 18 (24) | 3 (20) | 51 (82) |
|
| Left bundle branch block | 54 (35) | 46 (61) | 0 (0) | 8 (13) |
|
| History of stroke/transischemic attack | 10 (7) | 6 (8) | 4 (27) | 0 (0) |
|
| Diabetes | 41 (27) | 19 (25) | 4 (27) | 18 (29) |
|
| |||||
|
| Beta-blocker | 75 (61) | 54 (75) | 7 (64) | 14 (34) |
|
| Diuretic | 74 (60) | 56 (78) | 8 (73) | 10 (24) |
|
| Antiplatelet | 18 (15) | 15 (21) | 0 (0) | 3 (7) |
|
| Oral anticoagulants | 21 (17) | 16 (22) | 2 (18) | 3 (7) |
|
| Amiodaron | 4 (3) | 4 (6) | 0 (0) | 0 (0) |
|
| Calcio-antagonist | 6 (5) | 3 (4) | 0 (0) | 3 (7) |
|
| Angiotensin-converting enzyme-inhibitor/angiotensin receptor blockers 2 | 51 (41) | 39 (54) | 5 (46) | 7 (17) |
|
| Digitalis | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
|
| |||||
|
| Less than 12 months | 29 (20) | 26 (36) | 2 (13) | 1 (2) |
|
| 12-36 months | 59 (41) | 43 (59) | 7 (47) | 9 (16) |
|
| More than 36 months | 57 (39) | 4 (6) | 6 (40) | 47 (83) |
aCRT-D: cardiac resynchronization therapy defibrillator.
bICD: single- or dual-chamber implantable cardioverter defibrillator.
cIPG + CRT-P: single- or dual-chamber pacemaker + cardiac resynchronization therapy pacemaker.
d124 patients with data about medication at baseline, 72 CTR-Ds, 11 ICDs, and 41 IPGs.
e145 patients with available date of implant, 73 CRT-Ds, 15 ICDs, and 57 IPGs.
Rate of transmission, overall and by priority.
| Transmission priority | All (n=153, 107 patient-years) | CRT-Da (n=76, 53 patient-years) | ICDb (n=15, 10 patient-years) | IPGc (n=61, 61 patient-years) | CRT-Pd (n=1, 1 patient-year) | |
|
| ||||||
|
| Transmissions, n | 654 | 426 | 50 | 176 | 2 |
| Annual rate of transmissions per 100 patient-years (95% CI) | 613 (568-662) | 802 (729-882) | 504 (382-665) | 410 (354-476) | —e | |
|
| ||||||
|
| Transmissions, n (%) | 551 (84.3) | 364 (85.4) | 40 (80.0) | 147 (83.5) | 0 (0.0) |
| Patients with green transmission, n | 141 | 67 | 14 | 60 | 0 | |
| Annual rate of transmissions per 100 patient-years (95% CI) | 517 (475-561) | 648 (585-718) | 393 (288-536) | 333 (283-391) | — | |
|
| ||||||
|
| Transmissions, n (%) | 88 (13.5) | 53 (12.4) | 9 (18.0) | 24 (13.6) | 2 (100) |
| Patients with amber transmission, n | 50 | 28 | 4 | 17 | 1 | |
| Annual rate of transmissions per 100 patient-years (95% CI) | 82.5 (66.9-102) | 94.4 (72.1-124) | 88.4 (46.0-170) | 54.3 (36.4-81.1) | 277 (69.2-1106) | |
|
| ||||||
|
| Transmissions, n (%) | 15 (2.2) | 9 (2.2) | 1 (2.0) | 5 (1.7) | 0 (0.0) |
| Patients with red transmission, n | 9 | 5 | 1 | 3 | 0 | |
| Annual rate of transmissions per 100 patient-years (95% CI) | 14.1 (8.5-23.3) | 16.0 (8.3-30.8) | 9.8 (1.4-69.7) | 11.3 (4.7-27.2) | — | |
aCRT-D: cardiac resynchronization therapy defibrillator.
bICD: single- or dual-chamber implantable cardioverter defibrillator.
cIPG: single- or dual-chamber pacemaker.
dCRT-P: cardiac resynchronization therapy pacemaker.
eNot applicable.
Figure 2(A) Distribution of transmission by priority; (B) low-priority detected events; and (C) high-priority detected events. CRT-D: cardiac resynchronization therapy defibrillator, ICD: single- or dual-chamber implantable cardioverter defibrillator, IPG: single- or dual-chamber pacemaker, CRT-P: cardiac resynchronization therapy pacemaker.
Figure 3Time from transmission to communication with the hospital.
Clinical response to reported events.
| Clinical response | Total (N=103), n (%) | Amber (n=88), n (%) | Red (n=15), n (%) |
| Heath care utilization required | 16 (15.5) | 7 (8.0) | 9 (60.0) |
| Hospitalization for device replacement | 7 (6.8) | 4 (4.5) | 3 (20.0) |
| Hospitalization for lead revision | 2 (1.9) | —a | 2 (13.3) |
| Hospitalization for cardiovascular reasons | 1 (1.0) | — | 1 (6.7) |
| In-office visit required | 6 (5.8) | 3 (3.4) | 3 (20.0) |
| Event resolved remotely | 87 (84.5) | 81 (92.0) | 6 (40.0) |
| New transmission required | 17 (16.5) | 11 (12.5) | 6 (40.0) |
| Not urgent actionb | 70 (68.0) | 70 (79.5) | — |
aNot applicable.
bEvent previously managed, monitoring the status of the event. The proportions are calculated on the total number of reported events (103, 88 amber, and 15 red).
Figure 4(A) Distribution of time from transmission to review, benchmarking phase versus external remote monitoring center (ERMC) phase; and (B) Percentage of reviewed transmissions, benchmarking phase versus ERMC phase. RM: remote monitoring.
Rate of reviewed transmissions, benchmarking phase versus external remote monitoring center phase.
| Device type | Benchmarking phase | Monitoring center phase | |||||
| Total exposure time (years) | Reviewed TXa, n | Annual rate of hospital physician reviewed TX per 100 patient-years (95% CI) | Total exposure time (years) | Reviewed TX, n | Annual rate of hospital physician reviewed TX per 100 patient-years (95% CI) |
| |
| Overall (patients, n=126) | 105 | 368 | 350 (316-387) | 89 | 78b | 88 (69-109) | <.001 |
| CRT-Dc (n=55) | 41 | 214 | 527 (461-603) | 39 | 42 | 108 (78-146) | <.001 |
| ICDd (n=12) | 10 | 35 | 366 (263-509) | 8 | 6 | 75 (28-163) | <.001 |
| IPGe (n=58) | 54 | 115 | 213 (177-255) | 41 | 5 | 12 (4-28) | <.001 |
| CRT-Pf (n=1) | 1 | 4 | 411 (154-1096) | 1 | 0 | —g | — |
aTX: transmissions.
b10 (14.7%) were classified as red.
cCRT-D: cardiac resynchronization therapy defibrillator.
dICD: single- or dual-chamber implantable cardioverter defibrillator.
eIPG: single- or dual-chamber pacemaker.
fCRT-P: cardiac resynchronization therapy pacemaker.
gNot applicable.